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Abstract
Background: b1-adrenaline receptor antagonists are often used to avoid circulatory complications during
anesthesia in patients with cardiovascular diseases. Of these drugs, esmolol, a short-acting b antagonist, is also
reported to exert antinociceptive and anesthetic sparing effects. This study was designed to identify the central
mechanism underlying the antinociceptive effect of esmolol.
Methods: Wistar rats (7-21 d, 17-50 g) were anesthetized with ketamine (100-150 mg/kg) or isoflurane (5%) and
decapitated. Horizontal slices (400-μm thick) of the lower brainstem containing the substantia gelatinosa (SG) of
the caudal part of the spinal trigeminal nucleus (Sp5c), in which the nociceptive primary afferents form the first
intracranial synapses, were made with a vibrating slicer. The miniature inhibitory and excitatory postsynaptic
currents (mIPSCs and mEPSCs, respectively) were simultaneously recorded from visually identified SG neurons of
the Sp5c in the presence of tetrodotoxin (1 μM). Additionally, mIPSCs were recorded during pharmacological
isolation of GABA- and glycine-mediated mIPSCs with kynurenic acid (1 mM).
Results: Esmolol (500 μM) significantly and selectively increased the mIPSC frequency (to 214.2% ± 34.2% of the
control, mean ± SEM, n = 35; P < 0.001), but not that of mEPSCs, without changing their amplitude. The increase
in mIPSC frequency with esmolol was not affected by prior activation of b receptors with isoproterenol (100 μM)
but it was significantly attenuated by removal of extracellular Ca
2+.
Conclusions: These data suggest that esmolol modulates inhibitory transmitter release in the Sp5c through a
mechanism involving Ca
2+-entry but in a b1-adrenoceptor-independent manner. The present results suggest that
the facilitation of inhibitory transmitter release in the central nociceptive network underlies, at least in part, the
antinociceptive effect of esmolol.
Background
Antagonists of the b adrenoceptors are frequently used
in patients with cardiovascular diseases to avoid circula-
tory complications during various types of operations
requiring anesthesia. Esmolol, a short-acting b1 antago-
nist, was recently reported to exert antinociceptive and
anesthetic-sparing effects in animals and human sub-
jects. For example, esmolol inhibits nociceptive
responses following formalin injection in rats [1],
reduces anesthetic requirements for skin incision during
propofol/N2O and morphine anesthesia in humans [2],
reduces the volatile anesthetic requirement in patients
receiving alfentanil [3], and reduces the intraoperative
use of inhalation anesthetic and fentanyl as well as post-
operative morphine consumption after perioperative
administration esmolol [4] (a thorough summary of the
analgesic and neuroprotective effects of b-blockers,
including esmolol, can be found in a review by Kadoi
and Saito, 2010) [5].
However, the mechanisms of such antinociceptive and
anesthetic-sparing effects of esmolol remain largely uni-
dentified. It is unlikely that such antinociceptive effects
are simply attributable to the blockade of b1 receptors
by esmolol because involvement of b1 receptors in the
regulation of nociception in the spinal cord is limited or
controversial [6-8]. In addition, a recent study indicated
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lol, blocks tetrodotoxin (TTX)-resistant Na channels
involved in nociceptive signaling in the dorsal root
ganglion [8], further suggesting that esmolol might exert
its antinociceptive effect independent of its b receptor
antagonism.
In addition to affecting the peripheral sensory systems,
another possible mechanism of esmolol’s antinociceptive
effects is modulation of the activity of central networks
underlying the transmission of nociceptive information,
such as those in the spinal dorsal horn and in the spinal
trigeminal nucleus [1,5,9]. In this study, we examined
whether esmolol affects the activity of the central noci-
ceptive network by recording spontaneously occurring
synaptic currents in the substantia gelatinosa (SG) neu-
rons of the caudal part of the spinal trigeminal nucleus
(Sp5c). The Sp5c was chosen because it is the primary
site of reception and modulation of thermosensitive and
nociceptive signals arising from the cranio-orofacial
regions, in which a variety of interneurons and projec-
tion neurons, together with a large number of bioactive
substances, play essential roles in the modulation and
integration of nociceptive information [10,11].
Methods
Brain slice preparation
The use of animals conformed to the Guiding Principles
for the Care and Use of Animals in the Field of Physio-
logical Sciences of the Physiological Society of Japan
(1988) and was approved by the Animal Care Commit-
tee of the Jikei University School of Medicine, Tokyo,
Japan. Wistar rats (7-21 days; weighing 17-50 g) of
either sex were anesthetized by intraperitoneal ketamine
(100-150 mg/kg) injection or brief isoflurane (5%) inha-
lation and decapitated immediately after the disappear-
ance of the righting reflex. Using a vibration slice cutter
(DTK-1000, Dosaka, Kyoto, Japan), two to three 400-μm
thick horizontal brain slices through the Sp5c were
made in ice-cold low-Ca
2+ and high-Mg
2+ artificial cere-
brospinal fluid (ACSF) containing (in mM) NaCl 125,
KCl 2.5, CaCl2 0.1, MgCl2 5.0, NaH2PO4 1.25, D-glucose
12.5, L-ascorbic acid 0.4, and NaHCO3 25 and saturated
with 95% O2 +5 %C O 2 (pH = 7.4). The slices were
incubated in “normal” ACSF (CaCl2 2m Ma n dM g C l 2
1.3 mM) for 30-40 min at 37°C and then kept at room
temperature until the recordings.
Whole-cell recording
Two types of internal solutions were used [1]. A “CsCl-
based” internal solution contained (in mM) 140 CsCl, 1
CaCl2, 2 MgATP, 1 EGTA, and 10 HEPES, pH 7.3, with
CsOH. The estimated equilibrium potential of Cl
- with
this internal solution was approximately 0 mV. This
solution was used to record miniature inhibitory
postsynaptic currents (mIPSCs) and miniature excitatory
postsynaptic currents (mEPSCs), which appear indepen-
dent of presynaptic action potentials. The frequencies of
mIPSCs and mEPSCs reflect spontaneous and tonic
transmitter release from inhibitory and excitatory presy-
naptic axon terminals, respectively. The mIPSCs were
recorded in isolation at a holding potential of -70 mV in
the presence of kynurenic acid (1 mM; an ionotropic
glutamate receptor blocker; Sigma) and TTX (1 μM; a
voltage-dependent Na
+ channel blocker; Alomone, Jeru-
salem, Israel), while mEPSCs were recorded in the pre-
sence of picrotoxin (100 μM; a GABAA and GABAC
receptor blocker; Sigma), strychnine (1 μM; a glycine
receptor blocker; Sigma), instead of kynurenic acid and
TTX [2]. A “low-Cl” internal solution contained (in
mM) 135 gluconic acid potassium, 0.1 CaCl2,2M g C l 2,
2 MgATP, 0.3 NaGTP, 1 EGTA, and 10 HEPES, pH 7.3,
with KOH. The estimated equilibrium potential of Cl
-
with this internal solution was -90 mV. This internal
solution was used to simultaneously record mEPSCs and
mIPSCs from SG neurons in the Sp5c. In these experi-
ments, the membrane potential was held around -40
mV, a value in between the reversal potentials of EPSCs
and IPSCs, enabling simultaneous but separate record-
ings of inward (excitatory) and outward (inhibitory)
postsynaptic currents. The tip resistance of the electrode
with these solutions was 3-7 MΩ.
The slices were secured in a recording chamber (~0.5
ml volume) and continuously perfused with ACSF at a
flow rate of 2-3 ml/min. Using infrared differential inter-
ference contrast optics or oblique illuminating systems
combined with videomicroscopy (BX51; Olympus,
Tokyo), the SG of Sp5c was identified as a lucent, ros-
trocaudally extending structure adjacent to the dark and
opaque rostrocaudally running bundles of the trigeminal
nerve at the lateral edge of the brainstem. The neurons
located in the SG were visually identified, and all
recordings were made from healthy-appearing neurons.
Immediately (within 10 s) after the membrane rupture
that established the whole-cell recording mode, we con-
firmed that the resting membrane potential was more
polarized than -45 mV without current injection and, by
rapidly manipulating the amplifier controls, that action
potentials in response to positive current injection were
overshooting. The cells without these properties were
rare in our experimental conditions and were discarded
when found. In the recordings with low-Cl internal solu-
tion, the resting potential and input membrane resis-
tance were measured 5-10 min after the establishment
of the whole-cell configuration. These values for the
neurons recorded with the CsCl internal solution were
not measured after stabilization because the resting
membrane potential was almost 0 mV due to K channel
blockade with Cs. The slices were perfused with “normal
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whole-cell configuration, and the data used for the ana-
lyses were sampled after at least a 10-min perfusion
with specific ACSFs containing drugs for pharmacologi-
cal isolation of the components of interest in each
experiment. Only one neuron in a slice was recorded for
pharmacological analyses. The nominally “Ca
2+ free”
ACSF contained 3.3 mM MgCl2 and 0.2 mM EGTA
(instead of 2 mM CaCl2 and 1.3 MgCl2)a n dw a su s e d
to examine the role of extracellular Ca
2+. The mem-
brane current was recorded with an AxoPatch 200B
(Axon Instruments). In a subset of the experiments,
evoked IPSCs (eIPSCs), which were evoked by focal sti-
mulation at a submaximal intensity (0.1 Hz; 0.08-0.5
mA; 100 μsec) with a bipolar concentric electrode
placed within the Sp5C near the recording site (< 500
μm), were recorded together with spontaneous IPSCs
(sIPSCs) in the absence of TTX and in the presence of
kynurenic acid (1 mM).
In general, if a sole application of an antagonist exerts
its effect by blocking a certain type of receptor, this
effect should depend on how much these target recep-
tors had been previously activated by endogenous
ligands. Because esmolol markedly facilitated release at a
much higher concentration than that at which it antago-
nizes b receptors, the b receptor agonist isoproterenol
w a sp r e - a p p l i e da t1 0 0μM 10 min prior to esmolol in
some of the experiments. Also, in a subset of cells, the
effects of landiolol, which is another b blocker with a
similar chemical structure to esmolol, were observed to
examine whether landiolol also facilitates mIPSCs.
In general, an increase in the frequency of miniature
postsynaptic events by a drug implies an effect on the
presynaptic release mechanism [12]. Accordingly, the
increase in mIPSC frequency, but not that of mEPSC, as
described in the Results, might indicate that esmolol
selectively affected GABAergic and/or glycinergic presy-
naptic terminals in the Sp5c.
We also analyzed the effect of extracellular Ca
2+
deprivation on esmolol modulation of mIPSC frequency
to examine whether the effect of esmolol depends on
the presence of extracellular Ca
2+ and its entry into the
presynaptic terminals, which is the most critical step of
transmitter release [13], to further identify the mechan-
ism underlying the increase in mIPSC frequency with
esmolol.
The signals were sampled with a PowerLab interface
(AD Instruments) at 4 kHz. The series resistance was
monitored but not compensated. The whole-cell capaci-
tance was monitored and compensated. There were no
apparent changes in the series resistance and whole-cell
capacitance during the recordings for the neurons used
in this study. The original traces in the figures and
curve-fitting calculations were made with the Igor Pro
graphic program (WaveMetrics). Postsynaptic currents
were identified first automatically and then manually
with visual identification of all events with IgorPro pro-
cedures written by F.K.
Drugs
Esmolol (gift from Maruishi, Osaka), landiolol (gift from
Ono Pharmaceutical, Osaka) and isoproterenol (Sigma)
were dissolved in ACSF and applied via the perfusion
line. Other compounds were purchased from Sigma or
Nacalai Tesque (Kyoto, Japan). All recordings were con-
ducted at room temperature (20 - 25°C).
Statistics
The values are expressed as the mean ± standard error
of the mean (SEM). Differences between the groups and
between recordings before and during drug applications
were examined with the nonparametric Mann-Whitney’s
U test for normalized values or Student paired t-test.
Differences with probability (P) < 0.05 were considered
significant. The concentration-response curves were
drawn by fitting a sigmoidal curve to the data points at
different drug concentrations using the curve-fitting
function of Igor Pro (WaveMetrics).
Results
First, we analyzed the effects of esmolol on spontaneous
action potential-independent postsynaptic currents
(PSCs) recorded in the SG neurons of Sp5c in the pre-
sence of TTX. In the first series of experiments, we
simultaneously recorded mEPSCs and mIPSCs using a
low-Cl internal solution and by holding the membrane
potential at -40 mV to examine whether esmolol exerts
selective and differential effects on the excitatory and
inhibitory transmissions in the same sets of neurons
(Figure 1A). The resting membrane potential and input
resistance for these neurons were -59.8 ± 0.5 mV and
182.0 ± 26.9 MΩ, respectively. Whereas esmolol mark-
edly and significantly increased the mIPSC frequency
(340.9% ± 174.3% (n = 5; P < 0.05) of the pre-esmolol
value), the frequency of simultaneously recorded
mEPSCs was not significantly affected by esmolol
(135.2% ± 22.4% (n = 5; P = 0.18) of the pre-esmolol
value; Figure 1A and 1B; summarized in Figure 1C; con-
nected markers plot in the center; n = 5). This conclu-
sion was also confirmed by the second series of
experiments, in which mEPSCs and mIPSCs were
recorded in separate sets of neurons under pharmacolo-
gical isolation with picrotoxin and kynurenic acid,
respectively, with a CsCl-containing internal solution at
a holding potential of -70 mV. This series of experi-
ments was performed because it allowed better identifi-
cation of even smaller amplitude events. Whereas the
frequency of mEPSCs recorded in isolation was not
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Figure 1 Selective increase in miniature inhibitory postsynaptic current (mIPSC) frequency by esmolol in neurons of the caudal part of
the spinal trigeminal nucleus (Sp5c). (A) Top: the membrane current recording of an Sp5c neuron at a holding potential of -40 mV. Esmolol
was applied at the horizontal bar. Middle: the time course of the changes in miniature excitatory postsynaptic current (mEPSC) frequency with
esmolol. Bottom: the time course of the changes in mIPSC frequency with esmolol. The abscissae of these graphs are identical (time; 5 min/div).
(B) 1 and 2 are time-extended traces taken at the points 1 and 2 in the trace in A (top). mIPSCs and mEPSCs (outward and inward events,
respectively) are marked with open circles above the traces and filled circles below the traces, respectively. (C) and (D) Summaries of the effects
of esmolol on mIPSC and mEPSC frequency, respectively. “cont”, mPSC frequency observed in 3-min control period before esmolol application
(filled markers and bars); “esmo”, those at 10-min application of esmolol (500 μM; open markers and bars). The numbers in parentheses indicate
the number of neurons tested and were used for the statistics. Left, results of recordings with “CsCl-based” internal solution (squares) under
pharmacological isolation of mIPSCs (C) and mEPSCs (D); center, results of recordings with “low-Cl
“ internal solution in five cells (circles) in which
mIPSCs (C) and mEPSCs (D) were simultaneously recorded (see Methods); right bars, pooled summaries based on the results with “CsCl” internal
solution and “low-Cl” solution. *, P < 0.05; NS, not significantly different from pre-administration values (100%). Paired t-test. (E) Concentration-
response relationship between esmolol and the changes in mIPSC frequency. The curve indicates the best-fit Hill equations for the data for
esmolol. The number of neurons used to estimate the mean values and curve-fitting was 39 (control); 5 (5 μM); 5 (50 μM); 4 (100 μM); 35 (500
μM); 7 (1500 μM). *, P < 0.02; Mann-Whitney’s U test; vs. control (no drug application). The horizontal broken line indicates the control values
(100%).
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Page 4 of 10significantly affected by esmolol (118.3% ± 33.1% (n = 7;
p = 0.57)), that of mIPSCs was significantly increased by
esmolol to 185.9% ± 26.9% (n = 30; P < 0.001). When
these responses are pooled, esmolol at 500 μM increased
the frequency of mIPSCs to 214.2% ± 34.2% (n = 35; P <
0.001) of the pre-application value, without significantly
affecting that of mEPSCs (125.3% ± 20.8% of the con-
trol; n = 12 neurons; Figure 1A and 1B). Esmolol (500
μM) did not exert a significant effect on the average
mIPSC amplitude (before esmolol, 21.9 ± 4.2 pA; during
esmolol, 21.8 ± 3.2 pA; P = 0.95; n = 6 neurons), sug-
gesting limited effects on postsynaptic responsiveness.
The increase in mIPSC frequency was dependent on the
concentration of esmolol (Figure 2) and was significant
at 500-1500 μM( P < 0.02; Figure 1). As the curve-fitting
of a Sigmoidal curve resulted in an EC50 value larger
than the whole estimated range, we concluded that the
EC50 of esmolol might be larger than the concentration
range examined (i.e., > 1500 μM; Figure 1D).
To directly examine whether the effects of esmolol on
mIPSC frequency depend on prior activation of b recep-
tors, we compared the effects of esmolol (500 μM) in
the absence and presence (10-min pretreatment) of iso-
proterenol (100 μM). This concentration of isoprotere-
nol gives rise to almost full activation of b receptors in
brain slice experiments (14). The mIPSC frequency was
not significantly affected by isoproterenol (112.9% ±
35.4% of the control, n = 6; P = 0.31). The increase in
mIPSC frequency with esmolol in the absence of isopro-
terenol (P < 0.01; Figure 2C, open circles) was not sig-
nificantly affected by the prior addition of isoproterenol
(100 μM; P = 0.04; Figure 2C, filled circles). As a whole,
the effect of esmolol in increasing mIPSC frequency was
not apparently affected by prior activation of b recep-
tors. In addition, we have examined effects of another
selective b1 antagonist, landiolol (Figure 2D and 2E).
Unlike esmolol (Figure 1E), landiolol, at concentrations
of 5-1500 μM, did not significantly affect mIPSC fre-
quency (Figure 2E); this finding further suggests that the
effect of esmolol involves mechanisms other than b
receptor blockade.
The mIPSC frequency was not significantly affected by
extracellular Ca
2+ deprivation (94.0% ± 15.7% of the
control, n = 14). While esmolol significantly increased
mIPSC frequency to 214.2% ± 34.2% of the control in
the presence of 2 mM Ca
2+ (P < 0.001; Figure 3A, C; vs.
pre-drug value (= 100%); Mann-Whitney U test), it only
changed the frequency to 125.3% ± 20.8% (n = 10),
which was not significantly different (P = 0.42) from the
pre-esmolol value, in the absence of extracellular Ca
2+
(Figure 3B, C).
We then analyzed the effects of esmolol on sIPSCs
and eIPSCs recorded in the SG neurons of Sp5c in the
absence of TTX. Esmolol (500 μM) significantly
increased sIPSC frequency (to 174 ± 35.4% of the con-
trol; n = 4) without significantly affecting the amplitude
of sIPSCs (before esmolol, 47.1 ± 9.1 pA; during esmo-
lol, 43.0 ± 8.3 pA: Figure 4A, C, E and 4F). In contrast
to the increase in the frequency of sIPSCs, esmolol sig-
nificantly decreased eIPSC amplitude to 35 ± 6.2% of
the control (Figure 4B and 4D). This decrease in eIPSC
amplitude was inversely related to the increase in sIPSC
frequency in each neuron (e.g. Figure 4D).
Discussion
By recording postsynaptic currents in the visually identi-
fied SG neurons in the Sp5c, we found that esmolol
modulates spontaneous inhibitory transmission. The
major findings are that 1) esmolol selectively increases
the frequency of mIPSCs and sIPSCs without affecting
that of mEPSCs, 2) esmolol decreases the amplitude of
eIPSCs without affecting that of either mIPSCs or
sIPSCs in the SG neurons of Sp5c, 3) the increase in
mIPSC frequency with esmolol requires extracellular
Ca
2+, and 4) this increase in mIPSC frequency with
esmolol does not require prior activation of b receptors.
Because the Sp5c is the primary center of integration
and modulation of primary afferent fibers carrying noci-
ceptive and thermosensitive information arising from
orofacial regions (15) and because inhibitory transmis-
sion is the primary mechanism determining the “gating”
of nociceptive information [16], these findings might
explain part of the basis for the analgesic effect of esmo-
lol described to date [1-3].
Mechanism of release facilitation
The mechanism through which esmolol facilitates the
release of inhibitory transmitters remains unidentified.
Interestingly, in the present preparation, extracellular
Ca
2+ deprivation did not significantly affect the basal
frequency of mIPSCs, suggesting that a large part of the
spontaneous release occurred through mechanisms inde-
pendent of Ca
2+ entry, which is a phenomenon com-
monly observed in the spinal SG [17] and the nucleus of
the solitary tract [12]. The present result indicates that
t h ei n c r e a s ei nm I P S Cf r e q u e n c yb ye s m o l o ld o e sn o t
involve facilitation of such Ca
2+ entry-independent
release. It is therefore likely that esmolol promoted the
process upstream to vesicle fusion [13,18]. The present
effects of esmolol are reminiscent of EPSC potentiation
by noradrenaline through an identified mechanism not
involving a and b adrenoceptors in the chick ciliary
ganglion synapses [19]. Yao [19] attributed this effect of
noradrenaline to an enhanced vesicle fusion probability
resulting from an increased Ca
2+ sensitivity of the exo-
cytotic process. Whether a similar mechanism underlies
the effect of esmolol in the SG of Sp5c remains
undetermined.
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Page 6 of 10Interestingly, esmolol exerted opposing effects on the
spontaneous and evoked IPSCs. Such contrasting effects
are reminiscent of the effect of BDNF on GABA and
glycine release in the spinal dorsal horn [20]. The pre-
cise cellular mechanisms underlying these opposing
effects of esmolol remain to be examined in future
studies.
Selective facilitation of inhibitory transmission
Another interesting feature of the release facilitation by
esmolol was its selective effect on inhibitory transmis-
sion. The most straightforward interpretation of this
selective facilitation is that the molecular mechanism
underlying this effect of esmolol is exclusively
expressed at GABAergic and/or glycinergic terminals.
This is not surprising because, for example, release
facilitation by activation of presynaptic Ca
2+-permeable
P2X receptors in the spinal dorsal horn occurs exclu-
sively at glycinergic terminals [17] and that in the
nucleus of the solitary tract [12] occurs only at gluta-
matergic terminals, owing to selective expression of
these receptors at glutamatergic terminals. We did not
pharmacologically identify whether these IPSCs were
mediated by GABAA receptors, glycine receptors, or
both. In the spinal dorsal horn of young animals, as
used in this study, glycine-only, GABA-only, and
mixed GABA/glycine IPSCs were recorded [21,22],
suggesting that the mIPSCs recorded in this study are
also composed of postsynaptic currents mediated by
these multiple inhibitory transmitters.
Such selective facilitation of inhibitory transmission
was also reported with nocistatin, a neuropeptide
shown to be involved in the development and/or mod-
ulation of hyperalgesia and allodynia. In the superficial
layer of the spinal cord dorsal horn of rats, nocistatin
selectively inhibits inhibitory, but not excitatory, trans-
mission, due to selective expression of its receptors in
the inhibitory interneurons in the SG [23]. Likewise, a
cannabinoid agonist selectively decreases mIPSC fre-
quency, but not that of mEPSCs, in rat cerebellar Pur-
kinje neurons, presumably due to the distinct roles of
intracellular Ca
2+ in generation of action potential-
independent release between the glutamatergic and
GABAergic terminals [24]. These examples suggest
that the molecular mechanism mediating esmolol’s
e f f e c t si se x p r e s s e ds e l e c t i v e ly at inhibitory terminals.
esmolol 500 μM
 5 min
 1 nA
1 2
1 s
 50 pA 
1 s
 50 pA 
 Ca
2+
 (+)
 Ca
2+
 (–)
250
200
150
100
50
0
*
10 35
NS
c
h
a
n
g
e
 
i
n
 
m
I
P
S
C
 
f
r
e
q
u
e
n
c
y
 
(
%
)
esmolol 500 μM
 5 min
 1 nA  12
A: Ca(+) ACSF
esmolol 500 μM
B: Ca(-) ACSF
C
12
12
Figure 3 The increase in miniature inhibitory postsynaptic
current (mIPSC) frequency by esmolol was dependent on
extracellular Ca
2+. (A and B) Top: the membrane current recording
of a neuron of the caudal part of the spinal trigeminal nucleus in
the presence (A) and in the absence (B) of extracellular Ca
2+.
Esmolol (500 μM) was applied at the horizontal bars. Recordings
with “CsCl-based” internal solution. Bottom of A and B: time-
expanded continuous traces taken at points 1 and 2 indicated in
the top traces showing the control and the peak effects of drugs.
(C) Summery of the effects of esmolol on mIPSC frequency. *, P <
0.001; Mann Whitney’s U-test. NS, not significantly different; vs. pre-
administration control values. The numbers in the bars indicate the
number of neurons analyzed. The horizontal broken lines indicate
the control values (100%).
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Page 7 of 10Because inhibitory transmission in the SG plays essen-
tial roles [17] in avoiding transmission of excessive
nociceptive signals to the higher centers and motor
systems involved in the withdrawal reflex [22], such
selective facilitation of inhibitory transmission should
prominently reduce nociceptive transmission, thus
resulting in an analgesic effect.
Molecular mechanism of esmolol effects and clinical
implication
Another interesting but unexpected feature of the facili-
tory effect of esmolol on mIPSC frequency found in this
study was that esmolol exerted this effect through an
unidentified mechanism not involving b1-adrenoceptor
blockade. The following three lines of evidence argue
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the spinal trigeminal nucleus (Sp5c). (A) The membrane current recording of an Sp5c neuron. Esmolol was applied at the horizontal bar. (B)
Traces showing evoked IPSC (eIPSC) waveforms (average of eight consecutive traces) evoked by stimulation before (1; left), during (2; middle)
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Page 8 of 10against an involvement of b1-adrenoceptor blockade in
the nociceptive effect of esmolol. First, the EC50 for the
increase in mIPSC frequency (> 1500 μM) was much
larger than that reported for b-receptor blockade (~10
μM). Second, landiolol, another short-acting b1-blocker,
did not exert detectable changes on mIPSC frequency in
the present preparation and experimental conditions.
Third, this effect of esmolol was not affected by prior
activation of b-receptors with isoproterenol. In addition,
the effect of activating b1 receptors on nociceptive sig-
naling in the spinal dorsal horn [25] remains controver-
sial [6,7]. At this moment, we have no candidate
molecule that might mediate such non-adrenergic
analgesic effects of esmolol. As the facilitory effect of
esmolol was observed at a relatively high concentration
(> 500 μM), it is possible that esmolol also blocked b2
receptors because of its small difference in binding affi-
nity (34-fold) [26]. However, it has been reported that
an activation, not a blockade, of b2 receptors has an
antinociceptive effect in animals with neuropathic pain
[27], making the involvement of b2 receptor blockade by
esmolol in mIPSC facilitation unlikely.
The mechanism underlying the effects described in
this study might be distinct from, but could be coopera-
tive with, the non-adrenergic inhibition of TTX-resistant
Na current with esmolol [8]. Notably, for technical rea-
sons, the present data were obtained in 7- to 21-day-old
rats (most were 10-21 days). To our knowledge, an
analgesic effect of esmolol in immature human subjects
or animals has never been examined or described. As
the inhibitory synaptic organization in the spinal cord
dorsal horn [21] undergoes postnatal modification, it
will be important in the future to confirm that such
effects of esmolol on spontaneous inhibitory transmis-
sion could be reproduced in more mature animals.
Conclusion
This study indicates that esmolol modulates inhibitory
transmitter release in Sp5c neurons through a mechan-
ism involving Ca
2+ entry and in a b1-adrenoceptor-inde-
pendent manner. Such release facilitation of inhibitory
transmitters might underlie, at least in part, the antino-
ciceptive effect of esmolol. Identification of the molecu-
lar target of such an effect of esmolol could lead to
better strategies for the management of operative and
persistent pain.
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